Showing results (71-80 of 87) with videos related to
Sort By:
Pageof 9
Ginekologia Polska|July 6, 2019
New therapeutic approaches in the treatment of node-positive cervical cancer patients based on molecular targets: a systematic reviewMarcin Sniadecki, Anna Swierzko, Mateusz Dabkowski, et al.Experimental and Molecular Pathology|February 15, 2023
Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancerAnna Jasiak, Magdalena Koczkowska, Maciej Stukan, et al.Frontiers in Endocrinology|May 25, 2026
Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategiesSzymon Chamerski, Katarzyna Wartecka-Zielińska, Filip Pomorski, et al.Cancers|November 17, 2018
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 PatientsMagdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, et al.Cancer|September 16, 2006
The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24Elfriede R Greimel, Karin Kuljanic Vlasic, Ann-Charlotte Waldenstrom, et al.Cancer Immunology, Immunotherapy : CII|June 8, 2013
Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumoursAgnieszka Szala, Sambor Sawicki, Anna St Swierzko, et al.Journal of Applied Genetics|November 5, 2014
Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencingMagdalena Ratajska, Magdalena Krygier, Maciej Stukan, et al.Oncology Reports|September 3, 2015
Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoformsMagdalena Ratajska, Magdalena Matusiak, Alina Kuzniacka, et al.Scientific Reports|May 22, 2015
Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an exampleKatarzyna Klonowska, Magdalena Ratajska, Karol Czubak, et al.Cancer Biomarkers : Section a of Disease Markers|July 31, 2023
Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinomaAdam Gorczyński, Kevin Miszewski, Yann Gager, et al.Pageof 9